Heinz Hammerlindl, PhD

Title(s)Postdoctoral Scholar, Pharmaceutical Chemistry
SchoolSchool of Pharmacy
Phone415-502-3196
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Cyclic tachyplesin I kills proliferative, non-proliferative and drug-resistant melanoma cells without inducing resistance. Pharmacol Res. 2024 Jul 18; 207:107298. Benfield AH, Vernen F, Young RSE, Nadal-Bufí F, Lamb H, Hammerlindl H, Craik DJ, Schaider H, Lawrence N, Blanksby SJ, Henriques ST. PMID: 39032840.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    2. Small molecule in situ resin capture provides a compound first approach to natural product discovery. Nat Commun. 2024 Jun 19; 15(1):5230. Bogdanov A, Salib MN, Chase AB, Hammerlindl H, Muskat MN, Luedtke S, da Silva EB, O'Donoghue AJ, Wu LF, Altschuler SJ, Molinski TF, Jensen PR. PMID: 38898025; PMCID: PMC11187115.
      View in: PubMed   Mentions:    Fields:    
    3. H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase. Drug Resist Updat. 2023 Nov; 71:100993. Ravindran Menon D, Hammerlindl H, Gimenez G, Hammerlindl S, Zuegner E, Torrano J, Bordag N, Emran AA, Giam M, Denil S, Pavelka N, Tan AC, Sturm RA, Haass NK, Rancati G, Herlyn M, Magnes C, Eccles MR, Fujita M, Schaider H. PMID: 37639774; PMCID: PMC10719180.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    4. Small Molecule in situ Resin Capture - A Compound First Approach to Natural Product Discovery. bioRxiv. 2023 May 30. Bogdanov A, Salib MN, Chase AB, Hammerlindl H, Muskat MN, Luedtke S, Barbosa da Silva E, O'Donoghue AJ, Wu LF, Altschuler SJ, Molinski TF, Jensen PR. PMID: 37398257; PMCID: PMC10312467.
      View in: PubMed   Mentions:
    5. Implantation of engineered adipocytes that outcompete tumors for resources suppresses cancer progression. bioRxiv. 2023 Mar 29. Nguyen HP, Sheng R, Murray E, Ito Y, Bruck M, Biellak C, An K, Lynce F, Dillon DA, Magbanua MJM, Huppert LA, Hammerlindl H, Esserman L, Rosenbluth JM, Ahituv N. PMID: 37034710; PMCID: PMC10081280.
      View in: PubMed   Mentions:
    6. Modulating environmental signals to reveal mechanisms and vulnerabilities of cancer persisters. Sci Adv. 2022 01 28; 8(4):eabi7711. Sun X, Bieber JM, Hammerlindl H, Chalkley RJ, Li KH, Burlingame AL, Jacobson MP, Wu LF, Altschuler SJ. PMID: 35089788; PMCID: PMC8797778.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Differential toxicity to murine small and large intestinal epithelium induced by oncology drugs. Commun Biol. 2022 01 27; 5(1):99. Bieber JM, Sanman LE, Sun X, Hammerlindl H, Bao F, Roth MA, Koleske ML, Huang L, Aweeka F, Wu LF, Altschuler SJ. PMID: 35087225; PMCID: PMC8795448.
      View in: PubMed   Mentions: 1  Translation:AnimalsCells
    8. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer. Theranostics. 2020; 10(14):6261-6277. Ravindran Menon D, Hammerlindl H, Torrano J, Schaider H, Fujita M. PMID: 32483452; PMCID: PMC7255038.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    9. Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer. Epigenomics. 2019 05; 11(7):732-737. Emran AA, Marzese DM, Menon DR, Hammerlindl H, Ahmed F, Richtig E, Duijf P, Hoon DS, Schaider H. PMID: 31070054; PMCID: PMC6595545.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    10. Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming. Clin Epigenetics. 2019 03 08; 11(1):43. Torrano J, Al Emran A, Hammerlindl H, Schaider H. PMID: 30850015; PMCID: PMC6408861.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCells
    11. Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma. Cancer Med. 2019 03; 8(3):1186-1196. Emran AA, Chinna Chowdary BR, Ahmed F, Hammerlindl H, Huefner A, Haass NK, Schuehly W, Schaider H. PMID: 30793515; PMCID: PMC6434221.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    12. Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget. 2018 Feb 02; 9(9):8206-8222. Emran AA, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, Flaherty K, Hoon DSB, Gabrielli B, Herlyn M, Schaider H. PMID: 29492189; PMCID: PMC5823586.
      View in: PubMed   Mentions: 42     Fields:    
    13. Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers. Clin Cancer Res. 2018 03 01; 24(5):1090-1102. Hammerlindl H, Ravindran Menon D, Hammerlindl S, Emran AA, Torrano J, Sproesser K, Thakkar D, Xiao M, Atkinson VG, Gabrielli B, Haass NK, Herlyn M, Krepler C, Schaider H. PMID: 29196297; PMCID: PMC5844814.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    14. Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance. J Cell Commun Signal. 2018 Mar; 12(1):133-141. Hammerlindl H, Schaider H. PMID: 29192388; PMCID: PMC5842196.
      View in: PubMed   Mentions: 28  
    15. Notch4 Signaling Induces a Mesenchymal-Epithelial-like Transition in Melanoma Cells to Suppress Malignant Behaviors. Cancer Res. 2016 04 01; 76(7):1690-7. Bonyadi Rad E, Hammerlindl H, Wels C, Popper U, Ravindran Menon D, Breiteneder H, Kitzwoegerer M, Hafner C, Herlyn M, Bergler H, Schaider H. PMID: 26801977; PMCID: PMC5167360.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    Heinz's Networks
    Concepts (67)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (18)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-5-g94c7c43e on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.